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Background: The transition metal copper enhances amyloid β aggregation and neurotoxicity, and in models of
concomitant amyloid and tau pathology, copper also promotes tau aggregation. Since it is not clear if the effects of
environmental copper upon tau pathology are dependent on the presence of pathological amyloid β, we tested
the effects of copper overload and complexing in disease models which lack pathological amyloid β.
Methods: We used cell culture and transgenic murine models to test the effects of environmental copper on tau
phosphorylation. We used oral zinc acetate as a copper lowering agent in mice and examined changes in blood
and brain metals through inductively coupled plasma mass spectroscopy. Behavioral effects of copper lowering
were assessed with Morris water maze and novel object recognition tasks. Changes in tau phosphorylation were
examined by phosphorylation specific antibodies on Western blots.
Results: In human neuroblastoma cells, excess copper promoted tau phosphorylation and a copper complexing
agent, tetrathiomolybdate, attenuated tau phosphorylation. In a transgenic mouse model expressing wild type
human tau, copper-lowering by oral zinc suppressed plasma and brain levels of copper, and resulted in a marked
attenuation of tau phosphorylation. No significant changes in behavior were observed with copper lowering, but a
trend to improved recognition of the novel object was observed in zinc acetate treated mice.
Conclusions: We propose that reduction of brain copper by blocking uptake of copper from the diet may be a
viable strategy for modulating tau pathology in Alzheimer’s disease. The potential benefits of this approach are
tempered by the absence of a behavioral benefit and by the health risks of excessive lowering of copper.
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Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease that manifests symptoms years after initial
abnormal processes begin. It is characterized pathologic-
ally by the presence of extracellular amyloid β (Aβ) pla-
ques and intracellular neurofibrillary tau tangles (NFTs).
The largest risk factor for AD is age, however increasing
evidence points to other environmental factors as play-
ing a role in AD. In particular, the transition metals zinc
and copper have been shown to be involved in the pro-
gression of AD. Studies examining metal levels in humans* Correspondence: quinnj@ohsu.edu
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unless otherwise stated.indicate an increase of copper during aging, and further
increased concentration of copper within AD brains [1].
Aβ has been shown to bind copper both in vitro and
in vivo [2]. The binding of copper induces spontaneous
aggregation at rates faster than in the absence of the
metals [3-6]. When bound to Aβ, copper can undergo
redox reactions and generate reactive oxygen species
extracellularly [7,8]. As well, copper is found concentrated
in NFTs [9], can bind to tau protein [10-12], and acceler-
ates aggregation rates in vitro [13]. Previous studies exam-
ining the effects of chronic copper exposure in 3×Tg mice
(APPswe, PS1, P301L tau), showed that copper increases
plaque formation and enhances tau phosphorylation [4].
Previous studies examining various copper lowering
therapies have attempted to chelate copper from the
brain. Clioquinol and its derivative PBT2 were developed
as blood brain barrier permeable chelators and hadd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and Aβ in the CSF [3,5,6,14,15]. Tetrathiomolybdate was
previously utilized by our lab in Tg2576 mice to chelate
copper from the brain, and showed reduced Aβ plaques
in a prevention paradigm, however not in a treatment
paradigm [16]. We recently published results utilizing
the Tg2576 mouse model and the systemic copper low-
ering therapy, zinc acetate [17]. This treatment works by
induced expression of metallothionein, resulting in a
Cu-metallothionein complex which prevents uptake of
copper in the gut. This treatment is utilized in humans
with Wilson’s disease, a genetic disorder resulting in
increased copper accumulation primarily in the liver,
brain and cornea [18]. In our study we found that inde-
pendent of genotype, oral zinc acetate administration
was able to reduce both blood and brain copper levels
while not affecting brain zinc levels [17]. This resulted in
decreased brain and blood copper, and reduced Aβ in-
solubility in a prevention paradigm, but not a treatment
paradigm. Another group has also examined the use of
zinc sulfate in the 3×Tg mouse model and observed de-
creased Aβ and tau phosphorylation [19]. Whether the
effect of copper on tau phosphorylation is independent
of the Aβ/copper interaction is yet to be determined.
We tested the hypothesis that copper modulates tau
phosphorylation in the absence of pathological Aβ in a
human neuroblastoma cell line (SH-SY5Y) and in a trans-
genic mouse expressing wild type human tau (hTau). The
SH-SY5Ycell line is a widely used model, including studies
of tau biology. The hTau mouse model was selected due
to the expression of full length wild-type human tau,
which more closely resembles idiopathic AD. This mouse
model contains the entire wild-type human tau gene with
the endogenous mouse tau gene disrupted, resulting in




The human neuroblastoma SH-SY5Y cells were obtained
from ATCC (CRL-2266) and grown in DMEM/F12
Media (11320–082 Gibco) and supplemented with 10%
FBS (16000–044 Gibco), non-essential amino acids
(NEAA) (11140–050 Gibco), and penicillin/streptomycin
(15140–122 Gibco). For experiments, cells were plated
in growth media with 10 μM retinoic acid (R2625
Sigma) (in DMSO) to induce outgrowth of projections
and upregulation of tau protein [20-22]. Copper was
added at concentrations up to 400 μM (in water), based
upon dosing studies to find a robust induction of tau
phosphorylation, and Tetrathiomolybdate (323446 Sigma)
was added at 3–90 μM (in DMSO). Cells were harvested
by scraping, followed by centrifugation, rinsing in PBS,
and homogenization by sonication in the same extractionbuffer used for brain homogenization (see below). Protein
concentrations were determined by BCA kit (23227 Pierce).
Animals and diet
The hTau strain is a double transgenic mouse crossed be-
tween the 8c (endogenous mouse tau with eGFP inserted
in exon 1) and Mapt (full length human MAPT that
expresses all six splicing isoforms on human promoter).
Mice were generated from a breeding pair generously pro-
vided by Dr. Glen Kisby. Male mice hemizygous for the
human microtubule-associated protein transgene were
harem bred with female murine microtubule-associated
protein knockouts. After weaning and genotyping, litters
were housed by sex with 4 mice per cage. Mice were
housed in a 12-hr light/12-hr dark cycle, and ad libitum fed
AIN-93M Purified Rodent Diet (Dyets Inc., Bethlehem, PA)
and water. We have previously used the AIN-93M Purified
Rodent Diet as a maintenance diet to control the amount
of baseline cupric carbonate (6 mg/kg), zinc carbonate (30
mg/kg), and other minerals and vitamins [23]. 70 g/kg of
soybean oil, containing 7% of an omega-3 fatty acid called
linolenic acid, is present in AIN-93M. The NIH Guidelines
for the Care and Use of Laboratory Animals were used for
the procedures and the Institutional Animal Care and Use
Committee of the Portland VA Medical Center approved
this study (Protocol Number: 1409). All behavioral studies
and handling were done to minimize animal suffering.
Treatments
HTau mice were randomized to either normal or zinc
acetate drinking water (zinc acetate from Mallinckrodt
Baker, NJ). Animal weights and ceruloplasmin (Cp)
activity were monitored to ensure zinc levels were not
detrimental to the animal’s well-being. In all of the treat-
ment cohorts, oral zinc acetate was administered at a
dose of 2 g/L vehicle in their drinking water for the first
four months, and then 1.5 g/L for the remaining two
months. Cp activity confirmed that mice were below the
target copper levels of 50% at 4 months, so the dose was
reduced to prevent complications. Females received an
effective dose of 176.59 mg Zn/kg mouse/day and males
received an effective dose of 143.6 mg Zn/kg mouse/day
(vehicle = DiH2O). Mice began receiving treatment at 12
months of age for a period of 6 months. At the end of
six months mice underwent behavioral training and were
euthanized.
Behavioral analysis
Spatial learning and memory associated with the hippocam-
pus was assessed using the Morris water maze (MWM) as
described in our previous studies [16,24,25]. Briefly, mice
were placed into the MWM tank for 6 trials each day for
7 days. The first two days were visual platform testing in
which the platform was slightly above the water with a
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equally between each quadrant to prevent bias towards any
given quadrant. Mice were given 60 seconds to find the
platform before being placed back in their cage. Forty-eight
hours after visible platform training, hidden platform train-
ing was conducted for five days. The target quadrant
became the upper right quadrant and the platform was not
moved during hidden platform training. The platform was
slightly submerged in opaque water and mice were given
60 seconds to find the platform. On the last day of hidden
platform training, the platform was removed from the tank
and mice were given a probe trial 2 hours after the final
training, in which they were allowed to swim freely in the
pool for 60 seconds. Seventy-two hours following the first
probe trial a second probe trial was conducted. The inter
trial interval for each trial was 10 minutes, except for
between trials 3 and 4 which were 2 hours and correspond
to the beginning of session one and session two for each
day. All MWM tasks were evaluated using an ANY-maze
video tracking system. Performance on visible and hidden
platform training was expressed as the mean ± standard
error of the mean (SEM) of the latency to platform
(in seconds). Performance on probe trials was expressed
as the mean ± SEM of the percent time in target quadrant
((seconds in quadrant/total seconds)*100) for all mice in
each treatment group.
Tissue homogenization
Following behavioral testing, animals were euthanized
according to the IACUC standard protocol of CO2
inhalation followed by cervical dislocation. Plasma was
collected by centrifugation of blood, and frozen. The left
hemisphere was utilized for analysis in this study. The
frontal cortex slice (the anterior 2 mm) and frontal slice
(the next 2 mm) were snap frozen on dry ice. The frontal
slice was used for inductively coupled plasma mass spec-
troscopy (ICP-MS), described below. The remaining left
hemisphere was divided into approximately equal anterior
and posterior fractions and snap frozen. The left anterior
portion of the brain was homogenized using an updated,
previously published protocol for amyloid extraction [26].
Briefly, tissue was homogenized by sonication in buffer,
termed AT+, containing: 10mM Tris pH 7.5, 1mM EGTA,
1mM DTT, 10% Sucrose, 1% Triton X-100, 1× protease
inhibitor cocktail (Sigma P8340), 1× phosphatase inhibitor
cocktail (Sigma P0044). Homogenates were centrifuged in
a TLA-100 fixed-angle rotor at 393,000 × g for 20 minutes
at 4°C a total of three times. After each spin, supernatants
were snap frozen on dry ice and pellets were re-sonicated
in original AT + buffer. Following the three spins, the
pellets were washed with water and again centrifuged.
Following this wash, the pellet was sonicated in 70%
formic acid to solubilize amyloid protein and a final
centrifugation step was performed.Ceruloplasmin assay
Blood was collected at baseline for every animal and then
every 4 weeks from 6 animals per treatment group,
rotated equally between animals. Up to 200 μl was ob-
tained from the saphenous vein. Cp activity was measured
from the beginning and end of treatment using a modified
version of the oxidase method that we have previously
reported [16]. Data was expressed as the mean ± SEM.Analysis of brain and plasma metals
Brain tissue (frontal slice) and plasma was analyzed for
zinc and copper levels using ICP-MS, following a previ-
ously used protocol [17]. Briefly for brain tissue, approxi-
mately 75 mg of tissue from male and female mice was
digested in 750 μl of concentrated HNO3 at 90°C for 1
hour. Once cooled, 750μl hydrogen peroxide was added
to each tube and 750μl 1% HNO3 was used to rinse the
sides. Briefly for plasma metals, 40 μl of plasma was
diluted 51× in 1% HNO3. ICP-MS was performed using
the previously reported parameters and standards [17].
Samples were analyzed in triplicate and averaged.Western blotting
SH-SY5Y and murine brain homogenates were analyzed
for various proteins through Western blotting. Proteins
were separated by SDS-PAGE with 10 μg per lane for SH-
SY5Y homogenates and 15μg for murine homogenates.
Protein was transferred to PVDF membrane and blocked
with 5% BSA. Primary (dilutions below) and secondary
antibodies (1:2500 dilution) were incubated on blots in
0.5% BSA. Antibodies used in this study are:
AT8 [phosphorylated S202/T205 tau] (Thermo) 1:500
mouse IgG, AT180 [phosphorylated T231/S235 tau]
(Thermo) 1:500 mouse IgG, PHF-1 [phosphorylated S396/
S404 tau] (Peter Davies) 1:500 mouse IgG, pT231 [phos-
phorylated T231 tau] (Thermo) 1:1000 rabbit IgG, Tau12
(Skip Binder) 1:5000 mouse IgG, GSK-3β total (Cell Signal)
1:1000 mouse IgG, Phosphorylated-GSK-3β S9 (Cell Signal)
1:1000 rabbit IgG, CDK5 (Cell Signal) 1:1000 rabbit IgG,
p35/p25 (Cell Signal) 1:500 rabbit IgG, and GAPDH
(Thermo) 1:5000 mouse IgG. Blots were imaged using a
Bio-Rad Gel Doc XR Imaging platform with Image Lab
software. Images were exported as *.tiff, quantified using
Image J, and assembled using Adobe Illustrator.Statistics
For the MWM and NORT, data was plotted using Graph-
Pad Prism 5 software (GraphPad software Inc.) and ana-
lyzed using both GraphPad Prism and R 3.0 (R Foundation
for Statistical Computing) as previously described [17].
Data for Western blotting was analyzed through Prism
using a one-sided student’s t-test for significance (p < 0.05).
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Copper enhances tau phosphorylation independent of Aβ
in neuroblastoma cells
Based upon previously published results [4,17], we sought
to determine if copper was able to induce tau phosphoryl-
ation in the absence of Aβ, indicating a potential direct
and independent effect. Cells incubated in the presence of
400 uM copper for 24 hours had higher amounts of phos-
phorylated tau at an AD relevant site as compared to theFigure 1 Copper affects tau phosphorylation. Varied copper and tetrath
in an effort to elucidate the effects of copper on tau phosphorylation, with
but not lower concentrations. Western blot bands for phosphorylated tau a
represented. * = p <0.05, ** = p <0.01, *** = p <0.001.cells incubated in the absence of copper (Figure 1). Lower
concentrations of copper were ineffective, and phosphoryl-
ation of tau at other AD sites was less robust (data not
shown). Incubation of cells with the copper complexing
agent tetrathiomolybdate (TM) attenuated copper-induced
tau phosphorylation in a dose-dependent manner (Figure 1).
We also examined the involvement of CDK5, a kinase
highly involved in tau hyperphosphorylation in AD and pre-
viously found to be affected by chronic copper exposure [4].iomolybdate concentrations were added to the media of SH-SY5Y cells
phosphorylation induced with copper at a concentration of 400 uM
t T231 were quantified. The mean ± the SEM of the band intensity is
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with TM treatment, but levels of the CDK5 activators
p35/p25 were reduced with increasing TM (Figure 1 and
Additional file 1). This shows that TM complexing copper
reduces the interaction of p35 and p25 (the neurotoxic
cleaved form of p35), leading to reduced tau phosphor-
ylation. Additionally cellular morphology and viability
looked normal (data not shown).
Zinc Acetate affects the levels of plasma ceruloplasmin
and plasma and brain copper, but not brain zinc levels, in
mice expressing wild type human tau
The major copper carrying enzyme in the blood is cerulo-
plasmin (Cp). Cp expression is regulated by systemic cop-
per, therefore, plasma Cp can be used as a surrogate
marker of copper status. We found a marked reduction in
plasma Cp activity in zinc treated male and female mice
as compared to untreated mice. We further analyzed theFigure 2 Metal levels in hTau mice after six months of treatment. (A)
ceruloplasmin, for both males and females and plotted as a percentage of
and zinc in the plasma (B and C respectively) and brain (D and E respectiv
μg of metal per gram of homogenized brain tissue. Data is represented asbrain metal composition of both copper and zinc using
ICP-MS to determine if systemic copper lowering pro-
duced lower brain copper levels and unchanged zinc
levels, as we have previously shown in other murine
models [17]. We found a significant reduction in brain
copper levels in zinc treated mice as compared to un-
treated mice (Figure 2). Importantly, brain zinc levels were
not increased by oral zinc administration, and paradoxic-
ally, oral zinc produced a slight, but significant lowering of
brain zinc in male mice. We also examined iron levels to
determine non-specific effects and found no changes in
plasma or brain iron (Additional file 2).
Lowering of brain copper results in decreased tau
phosphorylation
Our proposed hypothesis was that a reduction in brain
copper levels would affect tau phosphorylation, as was
shown in previous studies and in our cell culture model.Copper levels in the plasma were determined by a surrogate,
the vehicle treated mice. ICP-MS was used to analyze levels of copper
ely). Metal levels are plotted as parts per billion (ppb) for plasma and
the mean ± SEM of all mice in the treatment group.
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using site specific anti-phosphorylated tau antibodies
(Figure 3). We found that in male hTau mice treatedFigure 3 Analysis of tau phosphorylation following zinc acetate treat
for male mice was analyzed for AT8 (202/205), AT180 (231), PHF1 (396/404)
reactivity. Bands were quantified and plotted as percentage mean ± SEM owith zinc acetate, the phosphorylation state of tau at
S202/T205 (AT8) and T231 (AT180) was significantly
reduced as compared to hTau mice that were untreated.ment. The soluble fraction of anterior left hemisphere homogenates
, Tau12 (total tau), CDK5, p35, p25, Total GSK-3β, and GSK-3βs9 (active)
f the vehicle treated mice for all mice in each treatment group.
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be affected by zinc acetate. Interestingly, we found that
the total amount of tau was increased when brain cop-
per was lowered. After adjusting for the ratio of pTau to
total tau, AT8, AT180 and PHF-1 were found to be
reduced with zinc treatment (Additional file 3). Female
mice showed highly variable reactivity to all phosphory-
lated tau antibodies regardless of treatment group (data
not shown). Additionally, we examined insoluble tau by
a total tau Western blot of the formic acid soluble and
Triton X-100 insoluble proteins and found no difference
between treatment groups (data not shown).
There are many kinases known to phosphorylate tau
at the sites reported here, however CDK5 and GSK-3β
have been previously examined in relation to chronic
copper exposure [4]. We examined the levels and activ-
ity of CDK5, previously reported to play a role during
chronic copper exposure, and GSK-3β, not previously
shown to play a role during chronic copper exposure.
We found in male hTau mice, the overall levels of CDK5
and the levels of the regulator p35/p25 were not signi-
ficantly affected by zinc acetate treatment (Figure 3).
However, in male hTau mice we observed both total
levels of GSK-3β and the inhibited form, phosphoryl-
ation at serine 9, decreased significantly with zinc acet-
ate treatment (Figure 3). While the reduction of total
and S9 phosphorylated GSK-3β were comparable, this
data suggests that copper lowering therapy may affect
the availability of GSK-3β, potentially reducing the like-
lihood of tau phosphorylation.
Learning and memory testing was unaffected by zinc
acetate
In our previous study, we observed that despite a reduction
in insoluble Aβ, there was no appreciable difference in the
learning and memory between control and zinc treated
mice. However, Aβ load correlates less well to cognition in
humans, as compared to tau aggregation. We first analyzed
our hTau mice utilizing the Morris Water Maze where we
found no differences in swim speed between genders or
treatment groups (data not shown). No significant differ-
ence was observed in learning by either visual platform or
hidden platform in the hTau mice, regardless of gender
(Figure 4A, B). When probed at 2 or 72 hours, we also
failed to see a difference in the target quadrant dwell time
between zinc and untreated mice, regardless of gender
(Figure 4C, D). Additionally, we examined the number of
crossings of the platform location and found no difference
between genders or treatment groups (data not shown).
We also assessed memory through the novel object re-
cognition test. Male mice treated with zinc acetate had a
longer amount of time spent with the novel object as
compared to the untreated mice (62% versus 51%), indi-
cating improved memory (Figure 4E).Discussion
These studies demonstrate that copper modulates tau
phosphorylation in the absence of pathological Aβ. This
is distinct from previous studies showing effects of copper
upon Aβ pathology or upon concomitant Aβ and tau
pathology [4,17,19,27], and so represents an additional
reason to consider copper-modulating strategies for the
treatment or prevention of neurodegenerative diseases in-
volving tau pathology, including AD. The phosphorylation
sites affected are disease-associated phosphorylation sites
which have been identified as candidate targets for the
prevention of AD. The relevance to human subjects with
AD is strengthened by the use of cell lines and animal
models which express wild type human tau, the gene
expressed in human AD. Importantly, zinc treatment did not
cause an increase in brain zinc confirming our prior experi-
ence and that of other laboratories [17]. This is important as
zinc also has been shown to affect tau phosphorylation
[28-31]. The marked reduction of tau phosphorylation with
brain copper reduction, with no increase in brain zinc,
indicates a copper dependent rather than a zinc dependent
mechanism for affecting tau phosphorylation in the brain.
At the same time, we recognize that these model sys-
tems are not ideal in other respects. Differentiated neuro-
blastoma cells are not fully differentiated neurons, and
there is no functional change in these cells to indicate any
consequences of tau phosphorylation. Additional experi-
ments with primary neurons will permit the assessment of
copper manipulations upon relevant markers of neuronal
health, such as dendritic complexity and spine number.
The concentration of copper required to induce tau phos-
phorylation in vitro is also a relative weakness, as this rela-
tively high concentration may not be physiologically relevant
and may represent a non-specific stressor (Additional file 4).
On the other hand, the 400 uM concentration employed
here is within range of the approximately 100 μM concen-
tration reported for human brain [32]. Reports of 4 fold
increased copper in the neuropil of AD brains [32] and
2–15 fold increased copper in plaques [33] may help justify
the use of very high copper concentrations in these experi-
ments. However, we also note that our measurements of
metals in brain tissue fail to distinguish between intra- and
extra-cellular levels, and also fail to assess bioavailability of
metals. Since other investigators have argued that intraneur-
onal levels of copper are specifically reduced in AD, our
“bulk” brain levels of copper may be misleading. In fact,
those investigators have presented evidence to suggest that
delivering more, rather than less, copper to CNS neurons is
the key to attenuating tau pathology [34]. Additional research
will be necessary to resolve these apparent discrepancies.
The hTau mice also have some limitations. They do
not develop neurofibrillary tangles or display neuronal
death, so the histological consequences of copper modu-
lation and tau phosphorylation are not evident in the
Figure 4 Memory and spatial learning evaluation following zinc acetate treatment. (A) Mice were trained for two days using a visual
platform raised above the water level. Data represents the mean ± SEM of the time to reach the platform in seconds, for all mice in the treatment
group. (B) The water level was raised and mice were trained to find the hidden platform using visual cues around the room. Each data point is
the average of six trials per day per mouse in each treatment group and represented as the mean ± SEM of the time to reach the platform in
seconds. Following hidden platform training, the mice were tested at (C) 2 hours and (D) 72 hours for the ability to remember where the hidden
platform was located. Data is presented as the mean ± SEM of the percentage of time spent in the target quadrant for all mice in the treatment
group. (E) Mice were analyzed for time spent with a novel object as a function of working memory. Data is represented as the mean ± SEM of
the percentage of total time spent with the novel object for all mice in each treatment group.
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assess the functional effects of these manipulations in
the mice by looking for changes in cognitive abilities. Al-
though there was no evidence of any treatment effect
upon hippocampal-dependent memory (Morris Water
Maze), there was a trend toward treatment efficacy upon
frontal cortex-dependent memory (Novel Object). We
used an hTau−/− and mouse tau (mTau) −/− strain to
compare behavioral changes of the mTau−/−, hTau+/+
strain. A more appropriate control for behavioral com-
parisons may have been the mTau+/+, hTau −/− strain.
However, the mice used in this study were still able to learn
the tasks, suggesting that they are suitable for detecting
symptomatic effects. Additional experiments in mice with
more robust tau pathology, neuronal damage, and behavioraleffects are under way and will help clarify whether the ob-
served effect on tau phosphorylation is functionally relevant.
Another limitation of this strategy is the health risks
of lowering systemic copper levels. There are both he-
matologic and neurologic complications of copper defi-
ciency which will require close monitoring if this copper
lowering approach is applied clinically. The dosage used
in mice in these experiments is based on previous dose
finding work to achieve copper lowering of 30-50%, which
was well tolerated by the mice in terms of body weight
and survival. Similarly, human subjects with Wilson’s
disease tolerate oral zinc therapy and achieve a negative
copper balance [35], so clinical application (with ap-
propriate monitoring) of zinc therapy for AD is at least
plausible.
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tion is modulated is not entirely clear, as the in vitro
studies implicate one kinase involved in tau phosphor-
ylation (CDK5) while the in vivo data implicate another
(GSK-3β). Resolution of this point will require addi-
tional experimentation, but may not be necessary for
decisions about translating this strategy to clinical situ-
ations in which modification of tau phosphorylation is
desirable, regardless of the kinase involved.Conclusion
In summary, we present evidence that human wild type
tau phosphorylation can be modulated by copper, and a
copper-modulating strategy suitable for human use is
effective in an animal model of tau expression. Translation
to human subjects is consequently possible, but justification
for such a trial depends on the demonstration that this
intervention is functionally important for brain neurons,
and will require careful monitoring to avoid adverse effects
from copper deficiency.Additional files
Additional file 1: Quantification of p35 and p25 bands from
Figure S1. Western blot bands for p35 and p25 were quantified. The
mean ± the SEM of the band intensity is represented. Brackets indicate
p < 0.05 between the two treatments.
Additional file 2: Iron levels in mouse brain and plasma after
zinc treatment. ICP-MS was used to analyze levels of iron in the
brain (A) and plasma (B). Metal levels are plotted as parts per billion
(ppb) for plasma and μg of metal per gram of homogenized brain
tissue. Data is represented as the mean ± SEM of all mice in the
treatment group.
Additional file 3: Plot of pTau to total tau for soluble mouse brain
fractions following zinc acetate treatment. Bands from Figure S3 for
AT8, AT180, PHF-1 and Tau12 were plotted as a ratio of the phospho-tau
species/total tau for each mouse and represented as mean ± SEM of all
mice in each treatment group.
Additional file 4 Low concentrations of copper do not affect tau
phosphorylation. Varied copper concentrations were added to the
media of SH-SY5Y cells in an effort to clarify whether copper at
concentrations below 400 uM affect tau phosphorylation. Western blot
bands for phosphorylated tau at T231 show no effect of exogenous
copper at concentrations from 5 to 100 uM.
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